Research overview
What is Thymosin Alpha-1?
Thymosin alpha-1 is a defined short peptide separated from larger thymic-fraction research. It is not Thymalin extract, Thymopentin, or full-length thymosin beta-4. Formulation and exact sequence matter.
What has research examined?
The multicenter placebo-controlled TESTS phase 3 trial enrolled more than 1,100 adults with sepsis and found no significant difference in 28-day all-cause mortality between Thymosin alpha-1 and placebo. An earlier smaller ETASS trial suggested possible signals but had a marginal primary comparison. A broader immune or infection-prevention claim is not supported by these mixed outcomes.
Sepsis-trial findings are not evidence for a supplier vial or routine immune enhancement. FDA raises quality and safety gaps. No medical use, amount, or preparation is advised.
Research references
- Thymosin alpha-1 TESTS placebo-controlled phase 3 sepsis trialBMJ
- ETASS controlled sepsis trialCritical Care
- Certain bulk substances that may present significant safety risksU.S. Food and Drug Administration
Calculation boundary
FDA says safety information for proposed compounded thymosin alpha-1 is inadequate and identifies peptide characterization/immunogenicity concerns. A generic syringe diagram cannot assess supplier-vial safety.